LLY vs. MRNA: Eli Lilly vs. Moderna Stock Comparison

November 11, 2026

How do Eli Lilly (LLY) and Moderna (MRNA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Eli Lilly (LLY) and Moderna (MRNA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but LLY is classified in Pharmaceuticals while MRNA is classified in Biotechnology.

Company profile comparison for Eli Lilly (LLY) and Moderna (MRNA)
Profile Item	LLY	MRNA
Name	Eli Lilly and Company	Moderna Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Biotechnology
GICS Sub-Industry	Pharmaceuticals	Biotechnology
Market Capitalization	1,206.07 billion USD	101.48 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	June 1, 1972	December 7, 2018
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

LLY

MRNA

GSPC

Eli Lilly (LLY) vs. Moderna (MRNA), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Eli Lilly (LLY) and Moderna (MRNA). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Eli Lilly (LLY) and Moderna (MRNA). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Eli Lilly (LLY) and Moderna (MRNA)
Metric	LLY	MRNA
Total Return (1Y)	52.36%	1,031.66%
Total Return (3Y, Annualized)	34.18%	58.68%
Total Return (5Y, Annualized)	41.08%	3.23%

Risk Profile

Drawdown History

LLY

MRNA

GSPC

Eli Lilly (LLY) vs. Moderna (MRNA), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Eli Lilly (LLY) and Moderna (MRNA). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Eli Lilly (LLY) and Moderna (MRNA)
Metric	LLY	MRNA
Volatility (1Y, Annualized)	35.34%	194.88%
Beta (5Y)	0.40	1.08
Max Drawdown (5Y)	-34.48%	-93.93%
Avg. Volume (3M)	2.52M	21.61M

Risk-Adjusted Performance

Risk-Return Positioning

LLY and MRNA are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Eli Lilly (LLY) and Moderna (MRNA)
Metric	LLY	MRNA
Sharpe Ratio (1Y)	1.36	5.27
Sortino Ratio (1Y)	2.29	20.44

Profitability

ROE (TTM)

Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Eli Lilly (LLY) reports 86.02%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max: 109.18%
LLY: 86.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.00%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
MRNA: -39.00%
Q1: -64.05%
Min: -167.77%

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Eli Lilly (LLY) reports 31.90%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY: 31.90%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-141.43%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
MRNA: -141.43%

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Eli Lilly (LLY) reports 53.66%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max: 83.12%
LLY: 53.66%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-557.93%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
MRNA: -557.93%

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Eli Lilly (LLY) and Moderna (MRNA)
Metric	LLY	MRNA
ROE (TTM)	86.02%	-39.00%
ROA (TTM)	21.06%	-13.26%
Net Margin (TTM)	31.90%	-141.43%
Operating Margin (TTM)	53.66%	-557.93%
Gross Margin (TTM)	83.63%	-66.02%

Growth

Revenue Growth

Eli Lilly (LLY) at 44.70% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Eli Lilly (LLY) reports EPS growth of 95.99%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Eli Lilly (LLY) and Moderna (MRNA)
Metric	LLY	MRNA
Revenue Growth (YoY)	44.70%	-39.92%
Revenue Growth (3Y CAGR)	31.69%	-53.30%
EPS Growth (YoY)	95.99%	--
EPS Growth (3Y CAGR)	51.71%	--

Financial Strength

Current Ratio (MRQ)

Both Eli Lilly (LLY) at 1.39 and Moderna (MRNA) at 2.30 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
LLY: 1.39
Min: 0.10

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.30

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MRNA: 2.30
Min: 0.10

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Moderna (MRNA) at 0.19 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.23 uses more debt funding than most peers.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max: 1.42
LLY: 1.23
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max: 1.42
Q3: 0.65
MRNA: 0.19
Median: 0.15
Q1: 0.02
Min: 0.00

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Eli Lilly (LLY) and Moderna (MRNA)
Metric	LLY	MRNA
Current Ratio (MRQ)	1.39	2.30
Debt / Equity (MRQ)	1.23	0.19
Net Debt / EBITDA	0.96	--

Dividends

Dividend Yield (TTM)

Moderna (MRNA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY: 0.49%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Moderna (MRNA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY: 21.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Eli Lilly (LLY) and Moderna (MRNA)
Metric	LLY	MRNA
Dividend Yield (TTM)	0.49%	0.00%
Dividend Payout Ratio (TTM)	21.71%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Eli Lilly (LLY) trades at 43.95 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max: 85.34
LLY: 43.95
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
MRNA: --

Eli Lilly (LLY) vs. Moderna (MRNA): MRNA does not report P/E ratio, so it has no value marker; LLY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Eli Lilly (LLY) at 13.95 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max: 58.18
Q3: 25.77
LLY: 13.95
Median: 7.30
Q1: 3.01
Min: 0.01

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.55

Max: 58.18
MRNA: 45.55
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Moderna (MRNA) at 11.58 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 29.96 prices even higher, above its industry range.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY: 29.96
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.58

Max: 13.53
MRNA: 11.58
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Eli Lilly (LLY) vs. Moderna (MRNA): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Eli Lilly (LLY) and Moderna (MRNA)
Metric	LLY	MRNA
P/E Ratio (TTM)	43.95	--
P/S Ratio (TTM)	13.95	45.55
P/B Ratio (MRQ)	29.96	11.58
Free Cash Flow Yield (TTM)	0.77%	0.29%